Rigel Announces Presentation Of Data From Analysis Of REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals announced promising data from a Phase 2 study of REZLIDHIA (olutasidenib) in patients with mutant IDH1 acute myeloid leukemia (AML) who were relapsed/refractory to prior venetoclax-based regimens. The data were presented at the EHA2023 Hybrid Congress.
June 07, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals' REZLIDHIA shows promising results in Phase 2 study for patients with mutant IDH1 AML who were relapsed/refractory to prior venetoclax-based regimens.
The positive results from the Phase 2 study of REZLIDHIA indicate that the drug has strong efficacy and safety in treating patients with mutant IDH1 AML who were relapsed/refractory to prior venetoclax-based regimens. This could lead to increased demand for the drug and potentially boost Rigel Pharmaceuticals' revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100